Medications

ALS drug gets rare second review at high-stakes FDA meeting

A closely watched experimental drug for Lou Gehrig's disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to approve the treatment for those with the fatal illness.

Neuroscience

Stem cell-gene therapy shows promise in ALS safety trial

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This combined stem cell and gene therapy can potentially ...

Diseases, Conditions, Syndromes

Pseudobulbar affect: An often-overlooked condition

"Understanding Pseudobulbar Affect," the inaugural publication of the new Insights & Implications in Gerontology series from The Gerontological Society of America, addresses an often overlooked or misunderstood condition ...

Neuroscience

Gene therapy approach shows promise in treating ALS

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the progressive loss of motor neurons in the brain and spinal cord responsible for voluntary movements and muscle control.

Medical research

ALS: Early disease mechanisms discovered

Currently, there is no cure for amyotrophic lateral sclerosis (ALS). Things could soon change, however. Researchers at FAU and the University of California San Diego (UCSD) have identified a protein that already displays ...

Genetics

New research could explain unknown causes of epilepsy

In many cases of epilepsy—a disorder that disrupts the normal pattern of electrical activity in the brain and often results in seizures—the underlying cause is unknown, according to the National Institute of Neurological ...

page 10 from 40